Skip to content

Effect of Leech Therapy in the Treatment of Mild (Grade-I) Essential Hypertension

Clinical Evaluation of Irsal-i-Alaq (Leech Therapy) in the Management of Zaghtuddam Qawi Ibtidai (Grade-I Essential Hypertension) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105792
Enrollment
60
Registered
2026-03-10
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: leech therapy, and Riyazat with DASH diet according to BMI.: leech therapy weekly total 5 sittings followed by Brisk walking, 100 steps per minutes for 20 minutes, 5 days a week and DAS

Sponsors

Department of Ilaj Bit Tadbeer
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Grade 1 hypertension patients Firstly diagnosed cases of hypertension or the cases who are not on hypertensive medication Hb% 10gm/dl or more Both genders Patients willing to take part in the study

Exclusion criteria

Exclusion criteria: Grade 2,3 hypertension (SBP 159mmHg or more and/or DBP 99mmHg BP or more). Excluding patients who have associated clinical conditions which are: Cerebro vascular disease, heart disease, renal disease, peripheral vascular disease, and advanced retinopathy. Patients suffering from psychiatric disorder. Patients with generalized skin infection. Patients with blood disorders like hemophilia, thrombocytopenia, etc. Patients with secondary hypertension. Pregnant women & lactating mothers. Patients who fail to give consent for the trial and follow up. Patients having abnormal ECG findings.

Design outcomes

Primary

MeasureTime frame
To evaluate the therapeutic effects of Irsal-i-alaq in the management of Zaghtuddum qawi Ibtidai (Grade-I Essential Hypertension)Timepoint: To evaluate the therapeutic effects of Irsal-i-alaq in the management of Zaghtuddum qawi Ibtidai (Grade-I Essential Hypertension)

Secondary

MeasureTime frame
To evaluate any adverse effects of leech therapy if exist.Timepoint: assessment of all changes at leech site or any systemic symptoms at initiation of the study at : 0, 7th, 14th ,21st,28th day

Countries

India

Contacts

Public ContactDr S M Alim

Department of Ilaj-bit-Tadbeer Faculty Of Unani Medicine AKTC, AMU, Aligarh

drmshoaib77@gmail.com9411491568

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026